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Age remains the main risk factor for developing Alzheimer's disease (AD) although certain 
metabolic alterations, including prediabetes and type 2 diabetes (T2D), may also increase this 
risk. In order to understand this relationship, we have studied an AD-prediabetes mouse model 
(APP/PS1) with severe hyperinsulinemia induced by long-term high fat diet (HFD), and an AD-
T2D model, generated by crossing APP/PS1 and db/db mice (APP/PS1xdb/db). In both, 
prediabetic and diabetic AD mice, we have studied underlying neuronal pathology and synaptic 
loss. At 26 weeks of age, when both pathologies were clearly established, we observed severe 
brain atrophy in APP/PS1xdb/db animals as well as cortical thinning, accompanied by increased 
caspase activity. Reduced senile plaque burden and elevated soluble Aβ40 and 42 levels were 
observed in AD-T2D mice. Further assessment revealed a significant increase of neurite 
curvature in prediabetic-AD mice, and this effect was worsened in AD-T2D animals. Synaptic 
density loss, analyzed by array tomography, revealed a synergistic effect between T2D and AD, 
whereas an intermediate state was observed once more in prediabetic-AD mice. Altogether, our 
data suggest that early prediabetic hyperinsulinemia may exacerbate AD pathology, and that fully 
established T2D clearly worsens these effects. Therefore it is feasible that early detection of 
prediabetic state and strict metabolic control could slow or delay progression of AD-associated 
neuropathological features.  
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Alzheimer's disease (AD) is the most common cause of dementia among elderly people and at 
present it has no successful treatment. Neuropathological features include senile plaques (SP), 
mainly composed of amyloid-β (Aβ), and neurofibrillary tangles, comprised of phosphorylated 
tau [1]. More than these classical lesions, synaptic loss and reduced expression of synaptic 
proteins are the strongest pathological correlate of dementia and have the potential to may be 
more reliable markers of the progression of AD [2-3].  
 
Although age remains the main risk factor for AD, the ultimate causes are not completely 
understood. Epidemiological, clinical and animal studies also support that prediabetes [4-6] and 
type 2 diabetes (T2D) [7-9] may also be influential risk factors to develop AD and since 
prediabetes, although still reversible, goes largely undiagnosed in the population, it might be a 
critical control point. Previous studies have described links between T2D and AD which associate 
both pathologies. Among others, insulin receptors in the central nervous system are highly 
expressed in cognition-related regions, such as cortex and hippocampus, consistent with evidence 
showing that insulin levels influence memory [10]. Aβ oligomers, likely the most toxic Aβ species, 
may directly interfere with insulin signalling in hippocampal neurons resulting in memory 
dysfunction [11]. Aβ accumulation is currently seen as a key step in the pathogenesis of AD [12] 
and insulin may regulate Aβ levels [13-14], as well as exacerbate inflammatory responses that 
promote pathological Aβ processing and deposition (for review see [15-17]). Furthermore, 
reduced brain insulin signalling in mouse models of diabetes increases tau phosphorylation and 
Aβ levels [18-19]. Nevertheless, the mechanisms underlying the relationship between diabetes 
and dementia have not been completely elucidated.  
 
Recently, various transgenic animal models have been developed in order to further explore this 
relationship and derived consequences, including prediabetic and diabetic AD models [20-21]. 
In the present study we have used two animal models: 1) a prediabetic hyperinsulinemic AD 
mouse line, induced by long-term high fat diet (HFD) administration to APPswe/PS1dE9 mice 
(APP/PS1) [20], and 2) a long-term type 2 diabetic AD mouse, by using a mixed model of AD 
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(APP/PS1 mouse) and a T2D (db/db mouse) (APP/PS1xdb/db) [19]. These mouse lines allowed 
us to study the specific role of both, prediabetes and T2D, in the development of AD pathology, 
including generation of Aβ species or brain atrophy, as well as specific neuronal alterations 
such as axonal curvature and synaptic loss. Together, our data suggest that early 
hyperinsulinemia is sufficient to exacerbate central pathology in APP/PS1 mice, and that this 






APPswe/PS1dE9 mice were obtained from the Jackson Laboratory (Bar Harbor, USA) [22-23]. 
Prediabetes was induced in wildtype and APP/PS1 mice as previously described [24] by feeding 
them with high-fat diet (HFD; 60% Kcal from fat, OpenSource, USA) from 4 weeks of age until 
sacrifice at 26-27 weeks of age. Wildtype and APP/PS1 mice received regular diet (RD) (SAFE 
A04. Augy, France).  
 
In order to compare the effects of prediabetes and diabetes on brain pathology, APP/PS1 mice 
were crossed with db/db mice (Harlan Laboratories, The Netherlands) [19]. In order to 
characterize the effect of type 2 diabetes on AD pathology, 26-27 weeks old animals were 
grouped as follows: control (APP/PS1-/-db/db+/+, APP/PS1-/-db/db+/-  mice), APP/PS1 (APP/PS1+/-
db/db+/+ and APP/PS1+/-db/db+/- mice), db/db mice (APP/PS1-/-db/db-/-) and APP/PS1xdb/db 
(APP/PS1+/-db/db-/- mice), since db/db mice only show diabetic phenotype when homozygous 
for the leptin receptor knockout (db/db-/-). In order to compare groups all mice were sacrificed at 
26-27 weeks of age, when induced prediabetes or T2D are completely established and AD 
related pathology has also commenced in APP/PS1 mice.  
 
All experimental procedures were approved by the Animal Care and Use Committee of the 
University of Cadiz, in accordance with the Guidelines for Care and Use of experimental 
animals (European Commission Directive 2010/63/UE and Spanish Royal Decree 53/2013). 
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2. Metabolic determinations 
 
Body weight, postprandial blood glucose and plasma insulin levels were determined 
immediately before sacrifice in all groups, as previously described [24]. Blood glucose levels 
were measured from nicked tails using the glucometer Optium Xceed (Abbott, United Kingdom). 
Plasma insulin levels were measured using ultrasensitive mouse enzyme-linked 
immunoabsorbent assay (ALPCO Diagnostics, Salem, NH).  
 
3. Tissue processing 
 
At 26-27 weeks of age, animals were overdosed with chloral hydrate (60 mg/Kg). Brains were 
harvested and immediately weighed. Cortical tissue was dissected from the right hemisphere 
and stored at -80ºC prior to use. A small portion of the sensorimotor cortex (~1mm3) was also 
dissected for array tomography studies and fixed as previously described [25]. Left hemispheres 
were fixed in 4% PFA for two weeks before 30 µm coronal brain sections were obtained using a 
Microm HM450 microtome (ThermoFisher, Spain) and stored in 50% polyethyleneglycol at 4ºC.  
 
4. Cresyl violet staining 
 
Sections were selected at 1.5, 0.5, -0.5, -1.5, -2.5 and -3.5 mm from Bregma [26], as previously 
described [24], in order to analyze the cortex from all mice groups. Sections were mounted with 
DPX (Sigma, St. Louis, MO, USA) and images were acquired using an optical Laser Olympus 
U-RFL-T microscope (Olympus, Japan) and MMIcellTools software. Cortical thickness was 
measured in frontal, parietal and temporal cortical sections using Adobe Photoshop Elements 
and Image J software.  
 
5. Caspase activation 
 
Caspases 3/7 activity was analyzed in cortical homogenates from all groups in this study using 
the Caspase-Glo 3/7 assay (Promega, Madrid, Spain), following manufacturer´s indications. 
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Briefly, 5-7 mg of cortex was homogenized in PBS supplemented with a protease cocktail 
(Sigma, USA). Samples were diluted with PBS (2 µg/µl) and 50 µl of tissue homogenate was 
added to 50 µl of Promega Caspase-Glo 3/7 assay solution. Samples were incubated 1 hour at 
room temperature, protected from light. Luminescence signal was measured in the Biotek 
Synergy Mx Microplate Reader and data were expressed as percentage of control values. 
 
6. Senile plaque quantification 
 
Cortical Aβ burden was quantified in consecutive sections to those used for cresyl violet staining 
as previously described [27]. Sections were incubated with anti-A  antibody 1:2000 (AB2287 
Millipore, USA) in 0,5% BSA overnight at 4ºC. Secondary antibody, donkey anti-rabbit Alexa 
Fluor 594 (Molecular Probes, OR, USA) 1:1000, in 0.5% BSA, was incubated for 1 h at room 
temperature. Tissue was incubated with thioflavin-S (TS) 0,005% (Sigma, USA) 10 min at room 
temperature for dense core SP. Sections were visualized with a laser Olympus U-RFL-T 
fluorescent microscope (Olympus, Japan). Images were acquired using MMIcellTools software 
and analyzed with Image J software to quantify Aβ and TS burdens.  
 
7. Aβ40 and Aβ42 levels 
 
Soluble and insoluble Aβ40 and 42 concentrations were measured in cortical homogenates 
using colorimetric ELISA kits (Wako, Japan, Aβ 40 ref: 294-62501 and Aβ 42 ref: 290-62601) as 
previously described [28]. Assay was run following manufacturer's indications and read at 
450nm. Data were expressed as ng/mg tissue. 
 
8. NeuN and DAPI staining 
 
PFA-fixed 30 µm sections were washed in PBS, pretreated with 70% formic acid for 10 min and 
subsequently blocked in 5% normal goat serum (NGS) and 0,5% Triton-X100 for 1h. Sections 
were immunostained with anti-NeuN antibody (Chemicon) 1:200 as previously described [29], 
and conjugated goat anti-mouse Alexa Fluor 594 was used as secondary antibody. Sections 
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were washed and stained with DAPI 1mg/ml (Sigma) (1:2000) to stain nuclei and TS (0.005%) 
to visualize SP. The percentage of NeuN-possitive cells (normalized by total cells stained with 
DAPI was quantified in the proximity of SP in APP/PS1, APP/PS1-HFD and APP/PS1xdb/db 
mice (up to 40 µm). Areas located far from SP were also compared with Control, Control-HFD 
and db/db mice using Image J software.  
 
9. Axonal inmunostaining 
 
Axonal curvature was determined by immunostaining with SMI-312R antibody (1:1000) 
(Covance, USA) on consecutive sections to those used for cresyl violet staining. Briefly, 
sections were pretreated with hydrogen peroxide 3% and Triton-X 0.5% 20 min at room 
temperature and blocked with 3% BSA 1 hour. Alexa Fluor goat anti-mouse 594 was used as 
secondary antibody (Molecular Probes, USA) 1:200, in 1% NGS for 1h at room temperature. 
Senile plaques (SP) were visualized by staining with TS (0.005% w/v). Micrographs of stained 
tissue were obtained with a Laser Olympus U-RFL-T fluorescent microscope (Olympus, Japan) 
and MMIcellTools software. Axon curvature ratio was calculated by dividing the end-to-end 
distance of a dendrite segment by the total length between the two segment ends. Axon 
distance to the closest SP was measured at three points along each dendrite and the average 
distance was taken from these three measurements [30]. Axon curvature ratio and distance to 
SP were measured using Image J software. Curvatures were pooled in 10 µm steps from SP up 
to 40 µm from the border, and neurites analyzed further from SP borders were considered in 
SP-free areas. In SP-free animals axon curvature was compared with those measured in 
APP/PS1 mice further than 40 µm from SP.  
 
10. Array tomography 
 
Array tomography in combination with immunohistochemistry is a powerful approach to assess 
synaptic density in small tissue blocks. Synaptic density was assessed in 26-27 week old mice. 
Tissue from all groups under study was prepared for array tomography as previously described 
[25]. Briefly, cortical samples were fixed in 4% PFA for 4 hours, dehydrated through increasing 
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serial dilutions of ethanol and immersed into LR White resin (Electron Microscopy Sciences) to 
polymerize overnight at 53 °C. Embedded blocks were cut into ribbons (70 nm) by ultracut 
microtome (Leica) using a Jumbo Histo Diamond Knife (Diatome). Sections were rehydrated for 
5 min with 50 mM glycine in TBS and blocked 5 min in 0.05% Tween and 0.1% BSA. Primary 
antibodies for PSD95 (Abcam, USA) and 6E10 for Aβ (Covance, USA) were incubated (1:50) in 
blocking buffer overnight at 4ºC. Secondary antibodies (Jackson ImmunoResearch, USA) were 
incubated at 1:50 in blocking buffer for 30 minutes. Sections were counterstained with 0.01 
mg/mL DAPI for 20 min. For each area of interest (identified by fiduciary markers, such as 
nuclei), images were obtained on 18–25 serial sections through the somatosensory cortex using 
a Zeiss AxioImager Z2 microscope (Zeiss, Germany). Each set of images were opened 
sequentially in Image J, aligned, and processed in Watershed software (courtesy of Brad Busse 
and Steven Smith) to detect puncta larger than 10 voxels in volume that were present in more 
than one consecutive section. Synapse densities were calculated by dividing the number of 
PSD95-positive puncta by the volume of tissue sampled. The combined role of SP "halo effect" 
and metabolic alterations on synaptic density was assessed up to 40 µm from plaque borders 
(in 10 µm steps) in SP-bearing groups. The number of PSD95 dots in SP-free mice was 
compared with APP/PS1 mice densities when distance from SP were >40 µm.  
 
11. Statistical analysis 
 
Control groups from prediabetic (wildtype-RD) and T2D (APP/PS1+/+db/db+/+ and 
APP/PS1+/+db/db+/-) studies were compared and no differences were observed. Therefore all 
animals were included as a single control group. Two-way ANOVA (groupXdistance from SP) 
was used to compare synaptic density and axonal curvature. Further analyses by one-way 
ANOVA for independent samples were performed for individual distance subsets studied. One-
way ANOVA was used to compare metabolic parameters, Aβ levels, caspase activation and 






1. Metabolic characterization 
 
Body weight was significantly increased in both control and APP/PS1 mice on HFD for 23 
weeks (table 1), and this effect was higher T2D mice, both db/db and APP/PS1xdb/db. Although 
a slight increase in glucose levels was observed in APP/PS1-HFD treated mice, differences did 
not reach statistical significance, and were below 300 mg/dl, as a control limit for diabetes [24]. 
Conversely, T2D mice showed a significant increase in glucose levels, clearly over 300 mg/dl, 
when db/db and APP/PS1xdb/db mice were compared (table 1). Plasmatic insulin was 
significantly increased in control-HFD mice and even higher values were detected in APP/PS1-
HFD mice (table 1), supporting long-term HFD as a model of hyperinsulinemia and prediabetes 
[24]. When we analyzed diabetic mice we also observed a significant increase in insulin levels 
in db/db and a slightly higher, non significant increase was also detected in APP/PS1xdb/db 
mice (table 1). 
 
2. T2D induced atrophy is worsened in AD-T2D mixed model 
 
A slight, non significant, reduction in brain weight was observed in APP/PS1-HFD mice. As 
previously reported, a significant reduction of brain weight was observed in db/db mice [24]. 
Brain weight reduction was maximal in APP/PS1xdb/db mice, suggesting a step-wise worsening 
effect from prediabetes to diabetes, and supporting a synergistic interaction between the 
presence of APP/PS1 transgenes and db/db induced metabolic alterations [20] (Figure 1A). In 
accordance with macroscopic observations, we detected a reduction of cortical thickness in 
db/db mice [31], that was further exacerbated in APP/PS1xdb/db mice (Figures 1B and 1C). 
 
3. Caspase activation and neuronal loss is progressively increased in AD-prediabetic and 
diabetic mice 
 
Caspases 3/7 activation were similar to controls in the cortex from APP/PS1 and APP/PS1-HFD 
mice. However, we detected a significant increase in activation of cortical caspases 3/7 in db/db 
mice. This effect was further increased in APP/PS1xdb/db mice (Figure 2A). The specific effect 
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of the atrophy and cell death, on neurons was also assessed. In SP-free areas, the percentage 
NeuN-positive cells was slightly reduced in APP/PS1-HFD mice, and this effect was worsened 
in db/db mice. Moreover, in APPP/PS1xdb/db mice neuronal loss was increased when 
compared with the rest of the groups (Figures 2B and 2C). In the close proximity of SP a 
relevant reduction in the NeuN+/DAPI ratio was detected in all groups (APP/PS1, APP/PS1-
HFD and APP/PS1xdbdb) when compared with SP free areas, however even higher reductions 
were observed in the mixed model, APP/PS1xdb/db also in the proximity of the plaques 
(Figures 2B and 2C). 
 
4. Altered Aβ pathology in prediabetic and diabetic APP/PS1 mice 
 
As previously shown, prediabetes and diabetes do not necessarily affect amyloid pathology in 
the same manner [19-21, 32]. We observed an overall increase of SP in prediabetic APP/PS1 
mice after long-term HFD, whereas a reduction in dense-core plaques stained with TS was 
observed in the mixed T2D-AD animal model (APP/PS1xdb/db) [19, 21] (Figures 3A and 3B). 
We corroborated these findings by measuring Aβ by ELISA and we detected increased 
insoluble Aβ40 levels in prediabetic APP/PS1 mice (Figure 3C). Treatment of APP/PS1 mice 
with HFD increased soluble Aβ40 and 42 levels, following a similar trend previously reported 
[20, 32], although differences only reached statistical significance in APP/PS1xdb/db mice, both 
for Aβ40 and 42 cortical levels (Figure 3C). As previously suggested, our data support a shift 
towards more toxic soluble species in our mixed APP/PS1xdb/db model.  
 
5. Diabetes worsens AD neurite curvature 
 
We analyzed neurite curvature as an indication of neuronal dysfunction, [33-35] in the proximity 
of SP bearing groups (APP/PS1, APP/PS1-HFD and APP/PS1xdb/db). We also compared 
neurite curvature in SP-free groups (control, control-HFD and db/db) and in SP-free areas from 
all APP/PS1 groups. Neurite curvature was not affected in control-HFD mice whereas a slight 
increase in neurite curvature was observed both in APP/PS1 and APP/PS1-HFD mice even in 
SP-free areas. This effect was more severe in db/db mice, suggesting that neuronal integration 
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is impaired in a T2D animal model. Furthermore, curvature ratios in SP-free areas were 
significantly worsened in APP/PS1xdb/db mice when compared to the rest of the groups, 
supporting a cross-talk between both pathologies (Figure 4A and 4B). Brain regions containing 
SP (APP/PS1, APP/PS1-HFD and APP/PS1xdb/db mice) presented increased curvature ratios, 
when compared to SP-free areas and mice without SP. This effect was worsened in animals 
harboring both T2D and AD (APP/PS1xdb/db) (Figures 4A and 4B). In plaque-bearing mice 
(APP/PS1, APP/PS1-HFD and APP/PS1xdb/db) we also analyzed the "halo" effect of SP on 
neurite curvature, by allocating measured neurons in 10 µm intervals from plaque border up to 
40 µm. As expected, curvature ratio increased as distance to plaques was reduced and we 
detected a groupXdistance effect when we compared among groups [F(8,4171)=1.967, *p=0.045]. 
Further analysis in different subsets revealed an intermediate increase of neurite curvature in 
APP/-PS1-HFD mice, that worsened in APP/PS1xdb/db mice (Figure 4C). 
 
6. Amyloid-plaque induced synaptic loss is increased in diabetic mice 
 
Synaptic density was reduced in APP/PS1 mice even far from SP. Interestingly, even in the 
absence of amyloid pathology, we also detected that db/db mice presented reduced synaptic 
densities, indicating that T2D alone can significantly impair synapses (Figures 5A and 5C). A 
significant reduction in synaptic density was detected in the close proximity of SP. This 
reduction was approximately 30% in APP/PS1 mice, compared to control mice, in the range of 
previous observations [25] and up to 50% reduction in APP/PS1xdb/db mice, supporting the 
synergistic effect between AD and T2D also on synaptic dysfunction (Figures 5A and 5C). 
Analysis also revealed a "halo" effect around SP, in agreement with previous work [25]. We did 
not detect a groupXdistance effect in synaptic density [F(8,1027)=0.99, p=0.440], however further 
analysis of individual subsets revealed an overall exacerbation of synaptic loss in 
APP/PS1xdb/db mice (Figures 5B and 5C). Soluble Aβ40 and 42 levels negatively correlated 
with synaptic densities, reaching statistical significance far from SP (Pearson´s correlations: 
Aβ40-synaptic density (ρ=-0.664**) and β42 -synaptic density (ρ=-0.599**, **p<0.01). The fact 
that plaque-induced synaptic toxicity was increased in APP/PS1xdb/db mice, and that synaptic 
 
 12 
density was still compromised far from SP (>40µm) in this group, supports a synergistic effect 




Previous epidemiological and pre-clinical studies support a close relationship between AD and 
T2D (for review see [10, 17], however the underlying mechanisms are not completely 
understood. It also remains unclear whether hyperinsulinemia and insulin resistance, indicative 
of a prediabetic state prior to T2D, may also induce or accelerate central pathology in AD. 
Indeed, glucose and insulin play a crucial role in maintaining normal brain activity, and alterations 
of insulin dependent functions could be associated with central pathological conditions observed 
in AD [10, 15-16, 20, 24]. In order to address the role of T2D and prediabetes on neuronal and 
synaptic alterations in AD, we induced a severe hyperinsulinemia by long-term HFD administration 
to APP/PS1 mice. We also used a mixed animal model that presents both T2D and AD 
(APP/PS1xdb/db mouse) [19]. All animals under study were analyzed at 26-27 weeks of age, 
when SP deposition has commenced in APP/PS1 mice [23], and prediabetes, or diabetes has 
been completely established. Only T2D mice (db/db and APP/PS1xdb/db) presented glycaemia 
levels over 300 mg/dl, which is considered the threshold for a diagnosis of diabetes in rodents [20, 
36]. HFD induced high insulin levels and this effect was worsened when diabetes was completely 
established. Prediabetic mice overweight increased in diabetic mice (both db/db and 
APP/PS1xdb/db). Altogether, metabolic parameters indicate a progressive worsening effect from 
prediabetes to completely established T2D.  
 
Neuronal and synaptic loss are major hallmarks of AD, and brain atrophy is observed in both AD 
and T2D patients; however, one of the main limitations of present AD mouse models is that they 
show very little neuronal loss [37]. Diabetic (db/db) mice showed a significant reduction in brain 
weight, as previously described [24] and this effect was worsened in combination of APP/PS1 
transgenes, suggesting that aggravated brain atrophy in APP/PS1xdb/db mice is due to a 
synergic effect between AD and T2D. Also, cortical grey matter was reduced in AD-T2D mice, 
which is in line with previous observations in T2D patients, who have diminished brain volume 
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and cortical grey matter [38-39]. Increased apoptosis in the APP/PS1xdb/db mice may be due 
to higher caspase activity. Indeed, we observed increases in caspase 3 and 7 in db/db mice, 
and even higher activity in APP/PS1xdb/db mice. Although caspase activation can not 
unequivocally determine cell apoptosis, it may contribute to synapse loss which ultimately 
casuses deafferntatiaion and cell death. [40]. Moreover NeuN/DAPI ratios were progressively 
reduced in prediabetic APP/PS mice, db/db and APP/PS1xdb/db mice, supporting a worsening 
prediabetes-to-diabetes effect. Reduced neuronal density might be due to increased gliosis, 
observed both in APP/PS1 and db/db animals [19]. However, our data in combination with 
previous studies, in which central proliferation and neurogenesis processes seem to slow with 
aging in db/db mice [31], might further underscore the mechanisms of the neurodegeneration 
which evolves in the mixed colony (APP/PS1xdb/db). Leptin signalling is involved in synaptic 
function, neurodegeneration or learning and memory formation [41-42], and therefor our 
observations might not exclusively due to diabetes. However, our AD-prone prediabetic model 
(APP/PS1-HFD) showed a small reduction in brain weight, cortical thickness and neuronal 
population, suggesting the possibility of an intermediate state, before T2D onset, that could 
reveal some early prediabetes-related loss of neuronal integrity.  
 
Whereas peripheral neuropathy has been widely addressed in T2D, central neuronal pathology 
associated is not so well characterized. It has been previously stated that, just as any other 
insulin-dependent metabolically active tissue, neurons also develop insulin resistance and can 
not respond to insulin, resulting in neuronal injury (for review see [43]). In order to further 
characterize the observed brain atrophy in our mixed model of T2D and AD, we examined 
neurite curvature, as an indicator of abnormal neuronal morphology correlated with neuronal 
dysfunction (Stern et al. 2004). In AD mice, SP plaques can distort neurites in the close 
proximity and a "halo" effect of neurite pathology is clearly observed surrounding the plaques 
[35]. Whereas this effect has been largely addressed in AD models, to our knowledge no 
previous assessment of central axon curvature has been performed in db/db mice.We observed 
that even in the absence of plaques, T2D in db/db mice is sufficient to distort neuronal 
curvature, suggesting that synaptic transmission is also dysfunctional [44]. As expected, the 
presence of plaques in APP/PS1 mice caused an increase of axonal curvature, that was 
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worsened in the proximity of the plaques. Comparison of SP-bearing transgenic mouse groups 
showed that prediabetic mice (APP/PS1-HFD) had a more robust "halo" effect on abnormal 
curvature which again suggests an intermediate state in case of prediabetic mice. Abnormal 
neurite curvature was further exacerbated in APP/PS1xdb/db mice. Since T2D is a metabolic 
disorder that also provokes micro and macrovascular complications, inflammation and 
increased oxidative stress [17], several mechanisms may be responsible for increased neuritic 
curvature in the combined T2D-AD mouse line (APP/PS1xdb/db), as previously observed in 
other AD models [30, 34-35]. While we did not perform behavioural studies, it has been 
previously shown that both prediabetes and diabetes-induced states in APP/PS1 mice 
significantly impair learning and memory abilities [19-20]. Moreover, metabolic alterations 
significantly correlate with central pathology in both models, supporting the role of metabolic 
alterations at central level. 
 
We also analyzed synaptic density by array tomography, allowing the study a great amount of 
synapses [25], represented by PSD95-positive synaptic puncta. We observed a similar profile to 
that detected for neurite curvature, with db/db mice displaying significant reduction of synaptic 
density, supporting the neurotoxic effect of T2D on the brain. Extensive evidence shows that A  
in different states of aggregation, ranging from soluble species to dense core plaques, are 
neurotoxic [25, 35, 45]. Prediabetic AD mice presented an intermediate state, displaying some 
synaptic loss. However, the largest reduction in synaptic density was observed in 
APP/PS1xdb/db mice and synapse loss is the strongest correlate of cognitive decline in AD [1]. 
It has been previously shown that the space occupied by SP dense core, results in almost a 
total loss of synapses [25] and we also observed that the striking reduction in PSD95-positive 
puncta in the close proximity of the plaques, which has been shown to coincide with a "halo" of 
oligomeric Aβ surrounding the plaques [25], was worsened in APP/PS1xdb/db mice. This 
observations are also in agreement with detected soluble Aβ levels: increased soluble A 40 and 
42 levels were detected in APP/PS1-HFD mice, which were even higher in APP/PS1xdb/db 
mice [19-21]. On the other hand SP burden was reduced in APP/PS1xdb/db mice, as previously 
described in this animal model [19, 46]. We can not exclude that Aβ might be preferentially 
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depositing as amyloid angiopathy in leptomeningeal vessels, instead of SP, in 
APP/PS1 mice. Our data might be in accordance with recent hypothesis on amyloid-
dependent and amyloid-independent stages of AD, with an initial phase mediated by 
soluble oligomeric and fibrilar Aβ accumulation that leads to disruption of the neuropil, 
loss of dendritic spines, remodeling of neurites, and inflammatory responses, followed 
by a second phase that would consist of the further development of tangles, and 
synaptic and neuronal loss [12]. It is feasible that the observed increase in toxic soluble 
species [47] might contribute to progressive synapse reduction in prediabetic and diabetic AD 
mice. The combination of AD with T2D may therefore shift Aβ pathology towards a more severe 
version of the disease, which ultimately contributes to abnormal axonal curvature and synaptic 
loss. 
 
Our data support a synergy between T2D and AD [19-20]. AD brain pathology was initially 
exacerbated in prediabetes and significantly worsened after diabetes was fully established. 
These data support the potential use of insulin resistance therapies and a tight metabolic control 
in diabetic patients, to prevent or delay associated central complications, including AD. 
Interestingly, our data on prediabetes suggests that, since this is still a reversible metabolic state, 
brain associated alterations could also be potentially reversible with good metabolic control, 
stressing the relevance of an early detection and management of insulin resistance. 
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Table 1. Effect of prediabetes and T2D on metabolic parameters in APP/PS1 mice 
 
 Body weight (g) Glucose (mg/dl) Insulin (ng/ml) 
Control 32.26±2.90 124.23±  4.80   0.93±0.174 
Control-HFD 39.75±2.29†† 129.63±11.29   6.52±1.69†† 
APP/PS1 30.51±1.05 125.04±  4.66   0.77±0.15 
APP/PS1-HFD 41.13±2.84†† 148.18±  9.88   8.45±2.31†† 
db/db 58.40±1.10** 455.67±43.72** 16.58±5.00** 
APP/PS1xdb/db 57.37±2.74** 445.73±41.59** 20.65±6.91** 
 
Metabolic parameters were determined in prediabetic mice (APP/PS1 and Control mice on 
HFD) as well as in diabetic mice (db/db and APP/PS1xdb/db). Data are representative of 8-31 
mice and differences were detected by one-way ANOVA followed by Tukey b test or Tamhane 
tests as required. Body weight was significantly increased in HFD treated mice and higher 
increases were observed in T2D mice [F(5,90)=64.36, **p<0.01 vs. rest of the groups, ††p<0.01 
vs. control and APP/PS1 groups]. Glucose levels were slightly increased in APP/PS1 mice on 
HFD, although differences did not reach statistical significance. Glucose levels were 
significantly increased in T2D mice, both db/db and APP/PS1xdb/db [F(5,90)=66.52, **p<0.01 vs. 
rest of the groups]. Insulin levels were increased in HFD treated mice and higher levels were 
detected in T2D mice. Although statistical differences were not detected, hyperinsulinemia was 
more severe in APP/PS1xdb/db mice [F(5,45)=9.5, **p<0.01 vs. rest of the groups, ††p<0.01 vs. 







Figure 1. Cortical atrophy in APP/PS1-HFD mice is worsened in APP/PS1xdb/db mice. A) 
Brain weight was compared in all groups under study. A slight reduction in brain weight was 
observed in APP/PS1-HFD mice. Further atrophy was observed in db/db mice and this effect 
was worsened in APP/PS1xdb/db mice [F(5,91)=37.5, **p<0.01 vs. rest of the groups, ††p<0.01 
vs. APP/PS1-HFD, control-HFD, APP/PS1 and control mice, ‡‡p<0.01 vs. control and APP/PS1 
mice]. B) Cortical thickness was reduced in db/db mice and further reduced in APP/PS1xdb/db 
mice. 1.5 mm [F(5,42)=12.091, **p<0.001 vs. rest of the groups, ††p<0.01 vs. control, control-
HFD, APP/PS1 and APP/PS1-HFD]; 0.5 mm [F(5,44)=13.24, **p<0.001 vs. rest of the groups, 
††p<0.01 vs. control, control-HFD, APP/PS1 and APP/PS1-HFD]; -0.5 mm [F(5,45)=13.20, 
**p<0.001 vs. rest of the groups, ††p<0.01 vs. control, control-HFD, APP/PS1 and APP/PS1-
HFD]; -1.5 mm [F(5,44)=18.78, **p<0.001 vs. rest of the groups, ††p<0.01 vs. control, control-
HFD, APP/PS1 and APP/PS1-HFD]; -2.5 mm F(5,44)=1.87, **p<0.001 vs. rest of the groups, 
††p<0.01 vs. control, control-HFD, APP/PS1 and APP/PS1-HFD]; -3.5 mm [F(5,43)=16.772, 
**p<0.001 vs. rest of the groups, ††p<0.01 vs. control, control-HFD, APP/PS1 and APP/PS1-
HFD]. C) Representative image of cortical thickness measured in all groups under study. 
Cortical thickness is indicated by green lines and measured. Scale bar=250 µm.  
 
Figure 2. Caspase activation is increased and proportion of neurons are reduced in 
APP/PS1xdb/db mice. A) Activation of cortical caspases 3 and 7 was significantly increased in 
db/db mice and this effect was exacerbated in APP/PS1xdb/db mice. Differences were detected 
by one-way ANOVA followed by Tuckey b test [F(5,26)=11.86, **p<0.01 vs. rest of the groups, 
††p<0.01 vs. control, control-HFD, APP/PS1 and APP/PS1-HFD]. B) A slight reduction in the 
NeuN+/DAPI ratio was observed far from SP in APP/PS1-HFD mice. Higher reductions were 
observed in db/db mice and this effect was worsened in APP/PS1xdb/db mice when compared 
with the rest of the groups [F(3,1120)=41.41, **p<0.01 vs. rest of the groups, ††p<0.01 vs. control, 
control-HFD, APP/PS1 and APP/PS1-HFD, ‡‡p<0.01 vs. Control and control-HFD. In the 
proximity of SP reduced NeuN+/DAPI ratios were observed when compared to SP free areas 
and this effect was worsened in APP/PS1xdb/db mice [F(2,371)=7.53, **p<0.01 vs. rest of the 
groups]. C) Representative images of NeuN+/DAPI ratios in all groups under study (NeuN-red, 




Figure 3. Amyloid pathology is altered in APP/PS1-HFD and APP/PS1xdb/db mice. A) Aβ 
deposits were increased after HFD treatment, whereas dense core SP were reduced in 
APP/PS1xdb/db mice measured by TS staining (anti-A  immunostaining [F(2,105)=20.70, 
**p<0.01 vs. rest of the groups, ††p<0.01 vs. Control] and TS staining ([F(2,104)=15.30, **p<0.01 
vs. rest of the groups, ††p<0.01 vs. Control]). B) Illustrative example of anti-A  and TS  
(green) staining in SP bearing groups. Scale bar=125 µm. C) Insoluble A  levels corroborated 
these observations and insoluble Aβ40 levels were increased in APP/PS1-HFD mice, whereas 
a significant reduction was observed in APP/PS1xdb/db mice [F(2,28)=13.70, **p<0.01 vs. rest of 
the groups, ††p<0.01 vs. Control] although no statistical differences were detected for insoluble 
Aβ42 levels [F(2,30)=2.85, p=0.074]. Measurement of soluble Aβ levels revealed an overall 
increase of both Aβ40 and Aβ4 in APP/PS1-HFD mice that reached statistical significance in 
case of APP/PS1xdb/db animals ([F(2,28)=10.28, **p<0.001 vs. APP/PS1 and APP/PS1-HFD 
groups] and [F(2,29)=8.25, ††p<0.001 vs. APP/PS1] respectively). Differences were detected by 
one-way ANOVA for independent samples followed by Tukey b or Tamhane tests as required. 
 
Figure 4. Neurite curvature was increased in APP/PS1-HFD mice and this effect was 
worsened in APP/PS1xdb/db mice. A) Curvature ratios were slightly increased in APP/PS1 in 
SP free areas when compared with control groups. Also, neurite curvature was significantly 
increased in db/db mice, and this effect was worsened in APP/PS1xdb/db mice when we 
compared SP free areas in all groups under study. Data are representative of 5 mice and 
differences were detected by one-way ANOVA followed by Tamhane test [F(5,4404)=101.206, 
**p<0.01 vs. rest of the groups, ††p<0.01 vs. control, control-HFD, APP/PS1 and APP/PS1-
HFD, ‡‡p<0.01 vs. control and control-HFD]. Curvature ratios were significantly increased in the 
proximity of SP, and this effect was worsened in APP/PS1xd/db mice when compared with 
APP/PS1 and APP/PS1-HFD mice  [F(2,283)=3.22, *p<0.01 vs. APP/PS1 and APP/PS1-HFD]. B) 
Illustrative images of axon curvature stained with SMI-312R antibody (red) and SP stained with 
TS (green). Representative axons are marked in purple. Increased curvature ratios were also 
observed in db/db mice when compared with control mice. SP-bearing mice also show a higher 
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neurite curvature ratio and this effect is increased in APP/PS1xdb/db mice. Scale bar= 20 µm. 
C) Curvature ratios were reduced with increased distances to SP, when plotted in 10 µm 
subsets, in plaque-bearing groups. We observed a distance X group effect, and further 
assessment of individual subsets revealed that APP/PS1xdb/db mice presented a significantly 
higher curvature ratio than APP/PS1 and APP/PS1-HFD mice, whereas prediabetic APP/PS1 
mice were similar to other groups. Differences were detected by one-way ANOVA for 
independent samples, follwed by Tukey b or Tamhane as required: <10 µm [F(2,284)=3.170, 
*p=0.043 vs. APP/PS1 and APP/PS1-HFD], 10-20 µm [F(2,621)=13.868, **p<0.01 vs. APP/PS1 
and APP/PS1-HFD], 20-30 µm [F(2,614)=16.154, **p<0.01 vs. APP/PS1 and APP/PS1-HFD, 
††p<0.01 vs. APP/PS1], 30-40 µm [F(2,532)=8.707, **p<0.01 vs. APP/PS1 and APP/PS1-HFD], 
>40 µm [F(2,2134)=148.493, **p<0.01 vs. APP/PS1 and APP/PS1-HFD].  
 
Figure 5. Array tomography analysis revealed reduction in synaptic density in diabetic 
mice. A) Synaptic density was determined by array tomography of PSD-95 labelled cortical 
slices.  In the absence of plaques, synaptic density was reduced in db/db mice as well as in 
APP/PS1 and APP/PS1-HFD mice (SP-free areas) when compared to controls. Differences 
were detected by one-way ANOVA for independent samples followed by Tamhane test 
[F(5,1148)=14.75, **p<0.01 vs. rest of the groups, ‡‡p<0.01 vs. control and control-HFD]. An 
overall reduction in synaptic density was observed in SP-bearing mice and this effect was more 
severe in case of APP/PS1xdb/db mice. Differences were detected by one-way ANOVA for 
independent samples followed by Tamhane test [F(2,146)=8,76, **p<0.01 vs. APP/PS1 and 
APP/PS1-HFD]. B) A "halo" effect on synaptic density was observed in SP-bearing mice, when 
10 µm steps from SP were used. An overall reduction of synaptic density was observed in 
APP/PS1xdb/db mice when compared with APP/PS1 mice. Differences were detected by one-
way ANOVA followed by Tukey b or Tamhane tests; <10 µm from SP [F(2,143)=12.9, ††p<0.001 
vs. APP/PS1], 10-20 µm [F(2,143)=10.42, **p<0.01 vs. APP/PS1 and APP/PS1-HFD groups], 20-
30 µm [F(2,142)=6.62, ††p<=0.004 vs. APP/PS1], 30-40 µm [F(2,130)=3.26, †p=0.04 vs. APP/PS1], 
>40 µm [F(2,486)=9.88, ††p<0.01 vs. APP/PS1]. B) Representative image of synaptic staining 
with PSD95 antibody for excitatory synapses (red), SP stained with 6E10 antibody (green) and 
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nuclear staining with DAPI (blue). A reduction in red puncta can be observed in db/db mice. An 
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